Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Enersense has been chosen as the main contractor of the Soidinmäki wind farm

Enersense International PlcPress Release 16 July 2021 at 10.00 a.m.A subsidiary of Enersense International Plc, a provider of zero-emission energy solutions, Empower PN Oy, which operates in the business area of Power, has signed an agreement with Tuulivoimayhtiö Pohjoistuuli Oy group for construction of a wind farm in Soidinmäki, Saarijärvi. The wind farm in Soidinmäki consists of seven power plants and the construction begins in August 2021. The project will be completed by the end of 2022 according to plans. Enersense will provide construction of the wind farm’s roads and platforms,

Publishing of Stockmann’s Half year financial report for January–June 2021

STOCKMANN plc, Press release 16.7.2021 at 10:00 EET Stockmann plc will publish the Half year financial report for January–June 2021 on Friday, 23 July 2021 at 8:00 a.m. EET. The press and analyst briefing will be held on 23 July 2021 at 10:00 as a live webcast, that can be followed by this link  or on the address stockmanngroup.com.  The recording and presentation material are available on the company's website after the event. Further information:Stockmann Media DeskMon–Fri 9–16 EET

RLS GLOBAL AB (publ) INTERIM REPORT, Q2, 2021

APRIL 1[st] – JUNE 3O[th] · Net sales amounted to TSEK 244 (TSEK 739) · Earnings before interest and taxes (EBIT) amounted to MSEK 8,5 (MSEK -5,6) · Other income TSEK 15 429 (TSEK 281) · Earning per share before dilution at SEK SEK 0,13 (SEK-0,09) · Cash flow from operating activities amounted to MSEK -6,280 (MSEK-5 472) · Liquid assets at the end of the period MSEK 6,9 (MSEK 30,3) · Equity ratio was 87% (91%) JAN 1[st] – JUNE 3O[th] · Net sales amounted to TSEK 302 (TSEK 1 112) · Earnings before interest and taxes (EBIT) amounted to MSEK 2,2 (MSEK-9,5) ·

Episealer® Talus: Case report with 5-years’ follow-up data accepted for publication

Episurf Medical (NASDAQ: EPIS B) today announces that a case report with 5-years’ follow-up data of the very first Episealer® Talus patient has been accepted for publication in the peer-reviewed scientific journal Foot & Ankle Surgery: Techniques, Reports & Cases (Holz J., Ryd L., Kaiser R., Hollander K., van Dijk N., Schneider S., Treatment of an Osteochondral Lesions of the Talus with a novel Patient-specific Metallic Implant: A Case Report with 5-year Follow-up and Review of the Literature., Foot & Ankle Surgery: Techniques, Reports & Cases, 2021). The publication will appear in volume 1,

Buy-backs of shares of series B in Saab during week 27-28 2021

During the period 9 July – 15 July 2021, Saab AB (publ) (LEI code 549300ZHO4JCQQI13M69) has repurchased in total 236.000 own shares of series B (ISIN: SE0000112385) as part of the share buy-back programme initiated by the Board of Directors in order to secure delivery of shares to participants in Saab’s long-term Share Matching Plan, Performance Share Plan and Special Projects Incentive.The share buy-back programme, which Saab announced on 11 June 2021, is being carried out in accordance with the Market Abuse Regulation (EU) No 596/2014 (“MAR”) and the Commission Delegated Regulation (EU)

BioStock: Iconovo receives order for nasal Covid-19 vaccine development

Earlier this year, two Swedish life science companies, Iconovo, which develops complete inhalation products, and ISR, which develops immunotherapies, came together to start working on an inhalable Covid-19 vaccine using Iconovo’s ICOone platform. Now, the two companies have announced another agreement, this time for developing a nasal application of the vaccine using Iconovo’s new version of ICOone, called ICOone Nasal. The new application will lead to a faster track through clinical studies and thus a quicker path to market for this much-needed therapy.Read the full article at biostock.se:

Interim Report 1 April – 30 June 2021

· Strong growth in key ratios – significant steps in the right direction · Sales growth of 230% – signs of a normalization within healthcare following the pandemic · Confirmed timetable for 510(k) application and several clinical milestones during H2 2021"We are continuing to establish a solid foundation for growth globally, and I can confidently say that based on the now available clinical results for the Episealer®, our operating environment is improving substantially. As the clinical acceptance for a mini-metal implant with excellent clinical results grows in the orthopaedic

Continued lower sales due to pandemic but some stabilization

Q2                                · Net sales reached SEK 6.1 (13.9) million. · Result after tax came in at SEK -19.7 (-11.7) million. · Earnings per share, basic and diluted, were SEK -0.14 (-0.08). · Cash and cash equivalents were SEK 64.8 (30.9) million. Significant events in Q1 ·Enzymatica’s sales in the quarter decreased compared with Q2 2020 because of the pandemic resulting in fewer common colds. However, the cold remedy market in Sweden and in other markets began to recover during the quarter. ·Enzymatica’s rights issue was completed on June 2nd and

Interim report January to June 2021

Press release, Sweden, Stockholm, July 16, 2021 TagMaster shows record sales with improved results Second quarter 2021 · Net sales increased during the second quarter by 29,2% to 88,9 MSEK (69,8) · Adjusted EBITDA increased during the second quarter by 68,9% to 10,7 MSEK (6,3), corresponding to an adjusted EBITDA margin by 12,0% (9,2) · Operating loss was 4,8 MSEK (-12,5) which correspond to operating margin of -5,3% (-18,2) · Profit for the period was 4,0 MSEK (-12,4) · Result per share was 0,27 (-0,85) SEK[1] · Cash flow from operating activities for the period

Interim Report 1 April - 30 June 2021

First quarter · Net sales increased by 17 percent and amounted to SEK 3,279 million (2,805). · Operating profit before amortisation of intangible non-current assets (EBITA) increased by 31 percent and amounted to SEK 402 million (306) corresponding to an EBITA margin of 12.3 percent (10.9). · Operating profit increased by 37 percent and amounted to SEK 332 million (243) corresponding to an operating margin of 10.1 percent (8.7). · Profit after tax increased by 36 percent and amounted to SEK 250 million (184) and earnings per share before/after dilution amounted to SEK 0.90 (0.

Episurf Medical: Expansion of the European sales organization

Episurf Medical (NASDAQ: EPIS B) today announces two additions to the European sales organization. JAMO Orthopaedics has been appointed agent for the Episealer® Knee and Episealer® Talus in certain areas in the UK. JAMO Orthopaedics is an orthopaedic distributor focusing on the Midlands, and acts as a distributor or agent for several global orthopaedic companies. JAMO Orthopaedic will work alongside Episurf Medicals existing sales force in the UK. “JAMO Orthopaedics are excited and proud to be working alongside Episurf in the UK. With an evermore need for patient specific implants to

Status on US FDA Advisory Committee for roxadustat

16 July 2021 07:00 BST Status on FDA Advisory Committee vote on roxadustat in anaemia of chronic kidney disease The Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) has voted 13 to 1 that the benefit-risk profile of roxadustat does not support approval for the treatment of anaemia in chronic kidney disease (CKD) in non-dialysis dependent (NDD) adult patients, and 12 to 2 that the benefit-risk profile of roxadustat does not support approval for the treatment of anaemia in CKD in dialysis-dependent (DD) adult patients. The FDA will

Getinge Interim Report January-June 2021: Strong recovery in products for surgery

“In total, sales increased by 3.6% organically compared with the second quarter 2020, and the order intake declined by 6.1% organically compared with 2020 when we received very large orders of advanced ICU ventilators”, says Mattias Perjos, President & CEO. “Cash flow remained strong and net debt in relation to EBITDA improved further”.The second quarter was characterized by a rapidly growing need for cardiovascular surgery products in North America and acute needs for advanced ICU ventilators in India to treat COVID-19 patients. In addition, the high delivery rate of Getinge’s world-

REPORT ON THE SECOND QUARTER 2021

ALL-TIME HIGH SALES AND EBIT SECOND QUARTER 2021 · Net sales were SEK 5,571 m (3,329); an increase of · 67%, of which 66% was organic growth. · Operating profit before depreciation and amortization (EBITDA) was SEK 1,100 m (504), representing a margin of 19.8% (15.1%). · Operating profit (EBIT) before items affecting comparability was SEK 955 m (361), representing a margin of 17.2% (10.9%). · Items affecting comparability were SEK -58 m (-61) · Operating profit (EBIT) was SEK 898 m (300), representing a margin of 16.1% (9.0%). · Profit for the quarter was SEK 560 m

Elos Medtech Interim Report January 1 - June 30, 2021

A STRONG QUARTER WITH CONTINUED GROWTH April - June 2021 · Net sales for the second quarter amounted to SEK 181.0 (118.3) million, an increase of 53 percent compared with the same period last year. Net sales in local currencies increased by 63 percent. · Operating profit amounted to SEK 26.5 (14.9) million, corresponding to an operating margin of 14.7 (12.6) percent. In the second quarter of last year government grant and subsidies due to Covid-19 had a positive impact of SEK 38.9 million on operating profit. · Earnings after net financial items amounted to SEK 22.8 (9.1)

Cloetta AB interim report Q2: April – June 2021

Strong rebound in both segments, with sales of Branded packaged products back at pre-pandemic levels and good progress on Pick & mix profitability.· Net sales for the quarter increased by 14.8 per cent to SEK 1,420m (1,237) including a negative impact from foreign exchange rates of 3.4 per cent. · Sales of Branded packaged products increased organically by 7.3 per cent during the quarter: 0.7 per cent in April, 17.8 per cent in May and 5.0 per cent in June. · Sales of Pick & mix increased organically by 79.6 per cent during the quarter: 85.4 per cent in April, 111.0 per cent in May

Interim report January-June 2021

· Profit from property management attributable to parent company shareholders amounted to SEK 2,249m (1,993), corresponding to an increase per share by 9 % to SEK 12.06 (11.07) · Long term net asset value amounted to SEK 418.12 per share (354.98) · Rental income amounted to SEK 4,249m (4,049) · Profit after tax attributable to parent company shareholders amounted to SEK 4,877m (1,874) corresponding to SEK 26.15 per share (10.41) Profit from property management for the period amounted to SEK 2,538m (2,347). Profit from property management attributable to parent company

Hexagon expands its smart digital reality capabilities with the acquisition of Immersal

Hexagon AB, a global leader in digital reality solutions, today announced the acquisition of Immersal Oy, a pioneer and leading innovator of spatial mapping and visual positioning solutions used to produce augmented reality (AR) applications.  AR applications enhance real-world experiences by augmenting a user’s visual perception with the display of digital content in the physical world. AR’s ability to weave context-specific, 3D information into physical spaces provides endless opportunities to save time, improve performance and reduce costs across a wide range of industries and

Q2 2021: Probi enters new strategic partnerships

Significant events during the second quarter · Net sales decreased by 12% (-3% adjusted for currency changes) to SEK 158 m (180) in Q2 and decreased by 3% (+8% adjusted for currency changes) to SEK 329 m (338) in H1. · EBITDA margin was 25% (32%) in Q2 and 26% (26%) in H1. · New partnership with Oriflame and launch of product based on Probi Digestis®. · New long-term research collaboration focusing on vaginal health with the Estonian company Tervisetehnoloogiate Arenduskeskus AS. · The number of shares and voting rights has been reduced by cancellation of the 250,000

Lagercrantz Interim Report 2021/22 Q1

First quarter (1 April – 30 June 2021) · Net revenue increased by 33% to MSEK 1,301 (977). · Organically, net revenue increased by 18%. · Operating profit (EBITA) increased to MSEK 212 (124), equivalent to an operating margin of 16.3% (12.7). · Profit after financial items increased by 94% and amounted to MSEK 180 (93). · Profit after taxes increased to MSEK 139 (70). Earnings per share after dilution amounted to SEK 2.24 for the moving 12-month period (SEK 1.91 for the 2020/21 financial year). · Return on equity was 25% (21). The equity ratio at the end of the

Orexo’s flagship pharmaceutical pipeline asset OX124 enters pivotal trial

· The first cohort of healthy volunteers has been dosed. New Drug Application (NDA) filing expected in the second half of 2022. · OX124 is designed to reverse the effect of overdoses caused by the most powerful synthetic opioids that today are behind the vast majority of fatal overdoses in the US · Upon approval Orexo will along with ZUBSOLV® and modia™ have the most comprehensive range of treatment options for people suffering from opioid use disorder on the US market Uppsala, Sweden – July 16, 2021 – Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) today announces that the company has

Stille AB: Interim Report Q2 2021

Stille AB (publ) publishes the report for the second quarter and first half of 2021. “A historically strong second quarter with growth in all markets which we operate”, comments CEO Hanna Ernestam Wilkman.Revenues for the second quarter increased by 39 percent to 40.6 MSEK (29.3) and operating profit to 5.2 MSEK (-1.5) compared to previous year. The growth is applicable to both Surgical Instruments (44 percent) and C-arm Tables (35 percent).  “I am pleased to see that demand for our products is returning in all markets where we are active, and it is particularly positive that the growth

Altered Nomination Committee and proposal for expanded Board in Knowit AB

Knowits current Nomination Committee has been adjusted to reflect the current onwership in the Company.Pursuant to the instruction to the Nomination Committee of Knowit AB, the Nomination Committee shall be appointed by the three largest shareholders that want to participate in its work, and also include the Chairman of the Board. Knowit’s current Nomination Committee, which was constituted in October 2020 ahead of the AGM 2021, has been adjusted to reflect the current ownership in the Company. Nordea Funds and Handelsbanken Fonder, which had appointed members in the Nomination Committee,

Episurf Medical: Update on Episealer® Patellofemoral System for the US market

Episurf Medical (NASDAQ: EPIS B) today announces that the development of the company’s Episealer® Patellofemoral System is progressing according to plan. The previously communicated plan to submit a 510(k) application before the end of the year to the US FDA for US market clearance is still valid. The design for the system is now set and final device testing is presently being conducted. Episealer® Patellofemoral System is an implant system with two implants for treatment of chondral and osteochondral lesions in the knee joint. Simultaneously, the company is preparing for a commercial

There are no items matching the current filter
There are no more items matching the current filter
Back to top